Was cash paid for the 3,800-share award to the Boston Scientific (BSX) director?

No cash was paid by David S. Wichmann for the 3,800-share award. The Form 4 shows a transaction price of $0.0000 per share, indicating a compensation-related grant of restricted stock rather than an open-market purchase of Boston Scientific shares.

Boston Scientific (NYSE: BSX) director receives 3,800-share restricted stock grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

WICHMANN DAVID S reported acquisition or exercise transactions in this Form 4 filing.

Boston Scientific director David S. Wichmann received an annual equity award of 3,800 shares of Common Stock on May 7, 2026. The grant was made at no cash cost to him and is structured as restricted stock that vests in full at the next annual stockholders’ meeting.

After this award, he directly owns 45,382 shares. The filing notes the grant reflects a value of $215,000, calculated by dividing that amount by the closing price of Boston Scientific’s common stock on the grant date.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider WICHMANN DAVID S

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	3,800	$0.00	--

Holdings After Transaction: Common Stock — 45,382 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Restricted stock award: 3,800 shares Shares owned after grant: 45,382 shares Award value: $215,000

3 metrics

Restricted stock award 3,800 shares Annual equity award granted May 7, 2026

Shares owned after grant 45,382 shares Direct holdings following the transaction

Award value $215,000 Equity award value divided by closing price on grant date

Key Terms

restricted stock, annual equity award, closing price

3 terms

restricted stock financial

"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders."

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

annual equity award financial

"Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders."

closing price financial

"Reflects a value of $215,000 divided by the closing price of common stock on the date of grant."

Form 4 Insider Transactions: What Each Field Means →

05/11/2026 - 04:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WICHMANN DAVID S

(Last)

(First)

(Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH

MASSACHUSETTS

01752-1234

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/07/2026		A⁽¹⁾		3,800	A	$0.0000	45,382	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Annual equity award in the form of restricted stock vesting in full upon the next annual meeting of stockholders. Reflects a value of $215,000 divided by the closing price of common stock on the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	05/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Boston Scientific (BSX) director David S. Wichmann report in this Form 4?

David S. Wichmann reported receiving an annual equity award of 3,800 shares of Boston Scientific Common Stock. The shares were granted at no cash cost to him and are structured as restricted stock that will vest in full at the next annual stockholders’ meeting.

How many Boston Scientific (BSX) shares does David S. Wichmann hold after this grant?

After the reported grant, David S. Wichmann directly owns 45,382 shares of Boston Scientific Common Stock. This total includes the newly awarded 3,800 restricted shares, which are scheduled to vest in full at the next annual meeting of stockholders, subject to the grant’s terms.

When do the restricted shares granted to the Boston Scientific (BSX) director vest?

The restricted stock granted to David S. Wichmann vests in full upon the next annual meeting of stockholders. Until that vesting date, the 3,800 shares remain subject to the award’s restrictions as described in the Form 4 footnote for this equity grant.

What is the stated value of the Boston Scientific (BSX) equity award reported in the Form 4?

The Form 4 footnote states the equity award reflects a value of $215,000. That value was determined by dividing $215,000 by the closing price of Boston Scientific’s common stock on the May 7, 2026 grant date to calculate the 3,800 restricted shares.

Is this Boston Scientific (BSX) Form 4 transaction an open-market buy or a compensation grant?

This Form 4 reflects a compensation-related grant, not an open-market purchase. The transaction is coded as an award acquisition of 3,800 restricted shares at a price of $0.0000 per share, forming part of David S. Wichmann’s annual equity compensation as a director.